{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:57:40Z","timestamp":1762887460236,"version":"3.45.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010313","name":"Heidelberg Engineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ogla.2023.06.005","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T11:55:43Z","timestamp":1687002943000},"page":"592-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-1659","authenticated-orcid":false,"given":"Ari","family":"Leshno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-0010","authenticated-orcid":false,"given":"Carlos Gustavo","family":"De Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2251-796X","authenticated-orcid":false,"given":"Mae","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5663-0533","authenticated-orcid":false,"given":"Jeffrey M.","family":"Liebmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2023.06.005_bib1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ophtha.2006.08.031","article-title":"Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension","volume":"114","author":"Ocular Hypertension Treatment Study Group","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib4","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0161-6420(02)01167-3","article-title":"The European glaucoma prevention study design and baseline description of the participants","volume":"109","author":"Miglior","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bjophthalmol-2013-303622","article-title":"External validation of the OHTS-EGPS model for predicting the 5-year risk of open-angle glaucoma in ocular hypertensives","volume":"98","author":"Takwoingi","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/archopht.123.10.1351","article-title":"Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma","volume":"123","author":"Medeiros","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2015-306757","article-title":"Monitoring ocular hypertension, how much and how often? A cost-effectiveness perspective","volume":"100","author":"Hern\u00e1ndez","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib8","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1167\/iovs.11-8186","article-title":"Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group","volume":"53","author":"De Moraes","year":"2012","journal-title":"Invest Opthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2023.06.005_bib9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archophthalmol.2010.20","article-title":"Delaying treatment of ocular hypertension: the ocular hypertension treatment study","volume":"128","author":"Kass","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archopht.117.5.573","article-title":"The ocular hypertension treatment study: design and baseline description of the participants","volume":"117","author":"Gordon","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.286.2.180","article-title":"Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation","volume":"286","author":"D'Agostino","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ogla.2023.06.005_bib12","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.ogla.2023.06.005_bib13","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1001\/archopht.1976.03910040719002","article-title":"Long-term epinephrine therapy of ocular hypertension","volume":"94","author":"Shin","year":"1976","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0161-6420(91)32296-6","article-title":"A\u00a0comparison of treated and untreated glaucoma suspects","volume":"98","author":"Schulzer","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib15","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/archopht.1989.01070020668025","article-title":"Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial","volume":"107","author":"Kass","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00417-002-0614-4","article-title":"Results of the betaxolol versus placebo treatment trial in ocular hypertension","volume":"241","author":"Kamal","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s004170000189","article-title":"Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial","volume":"238","author":"Heijl","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0161-6420(89)32688-1","article-title":"A\u00a0long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects","volume":"96","author":"Epstein","year":"1989","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0002-9394(66)91483-8","article-title":"Topical epinephrine in glaucoma suspects","volume":"62","author":"Becker","year":"1966","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0002-9394(01)01338-1","article-title":"The ocular hypertension treatment study: reproducibility of cup\/disk ratio measurements over time at an optic disc reading center","volume":"133","author":"Feuer","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajo.2018.11.006","article-title":"Assessment of the impact of an endpoint committee in the ocular hypertension treatment study","volume":"199","author":"Gordon","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archophthalmol.2011.337","article-title":"The 10-year incidence of glaucoma among patients with treated and untreated ocular hypertension","volume":"129","author":"Gordon","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0341","article-title":"Assessment of cumulative incidence and severity of primary open-angle glaucoma among participants in the ocular hypertension treatment study after 20 years of follow-up","volume":"139","author":"Kass","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16290","article-title":"Surveillance for ocular hypertension: an evidence synthesis and economic evaluation","volume":"16","author":"Burr","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ogla.2023.06.005_bib25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ophtha.2007.08.012","article-title":"Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma","volume":"115","author":"Medeiros","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2008.08.051","article-title":"Visual field progression in the collaborative initial glaucoma treatment study the impact of treatment and other baseline factors","volume":"116","author":"Musch","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0161-6420(97)30172-9","article-title":"Effect of surgery on visual field progression in normal-tension glaucoma","volume":"104","author":"Bhandari","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/IJG.0000000000001906","article-title":"The association between intraocular pressure and visual field worsening in treated glaucoma patients","volume":"30","author":"Yohannan","year":"2021","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ogla.2023.06.005_bib29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bjophthalmol-2016-308948","article-title":"Rates of glaucomatous visual field change after trabeculectomy","volume":"101","author":"Baril","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/aos.12073","article-title":"Rates of visual field loss before and after trabeculectomy","volume":"92","author":"Bertrand","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib31","doi-asserted-by":"crossref","first-page":"e1127","DOI":"10.1111\/aos.15048","article-title":"Effects of glaucoma surgery on visual field progression in open-angle glaucoma considering the floor effect","volume":"100","author":"Schlatter","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/bjophthalmol-2016-309643","article-title":"Effects of ocular and systemic factors on the progression of glaucomatous visual field damage in various sectors","volume":"101","author":"Asaoka","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/IJG.0000000000001401","article-title":"Baseline age and mean deviation affect the rate of glaucomatous vision loss","volume":"29","author":"Bommakanti","year":"2020","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ogla.2023.06.005_bib34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ophtha.2009.10.016","article-title":"Beta-zone parapapillary atrophy and the velocity of glaucoma progression","volume":"117","author":"Teng","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ophtha.2009.06.028","article-title":"Factors affecting rates of visual field progression in glaucoma patients with optic disc hemorrhage","volume":"117","author":"Prata","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2023.06.005_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2022.02.003","article-title":"Glaucomatous visual field progression in the African descent and glaucoma evaluation study (ADAGES): eleven years of follow-up","volume":"239","author":"Melchior","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/archophthalmol.2011.72","article-title":"Risk factors for visual field progression in treated glaucoma","volume":"129","author":"De Moraes","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ogla.2023.06.005_bib38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jamaophthalmol.2020.1902","article-title":"Evaluation of a primary open-angle glaucoma prediction model using long-term intraocular pressure variability data: a secondary analysis of 2 randomized clinical trials","volume":"138","author":"Gordon","year":"2020","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419623001072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419623001072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:54:03Z","timestamp":1762887243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419623001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2589419623001072"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2023.06.005","relation":{},"ISSN":["2589-4196"],"issn-type":[{"type":"print","value":"2589-4196"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2023.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}